

Publications Dr. Dr. Venturelli:

1. Busch C, Burkard M, Leischner C, Lauer UM, Frank J, **Venturelli S**. Epigenetic activities of flavonoids in the prevention and treatment of cancer. *Clin Epigenetics* 2015; doi: 10.1186/s13148-015-0095-z.
2. **Venturelli S**, Sinnberg TW, Niessner H, Busch C. Molecular mechanisms of pharmacological doses of ascorbate on cancer cells. *Wien Med Wochenschr.* 2015; doi: 10.1007/s10354-015-0356-7.
3. Sinnberg TW, **Venturelli S**, Niessner H, Busch C. Hochdosis-Vitamin C als Krebstherapie: Molekulare Wirkmechanismen. *OM & Ernährung* 2015; 150: F22-F29.
4. Busch C, Noor S, Leischner C, Burkard M, Lauer UM, **Venturelli S**. Anti-proliferative activity of hop-derived prenylflavonoids against human cancer cell lines. *Wien Med Wochenschr.* 2015; doi: 10.1007/s10354-015-0355-8.
5. **Venturelli S**, Sinnberg T, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C. Epigenetic impacts of ascorbate on human metastatic melanoma cells. *Front Oncol.* 2014; doi: 10.3389/fonc.2014.00227.
6. Sinnberg T, Noor S, **Venturelli S**, Berger A, Schuler P, Garbe C, Busch C. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1 α in the NCI60 cancer cell lines. *J Cell Mol Med.* 2014; 18: 530-541.
7. **Venturelli S**, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, Häcker S, Schenk M, Schulze-Osthoff K, Salih HR, Fulda S, Sipos B, Johnstone RW, Lauer UM, Bitzer M. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. *Mol Cancer Ther.* 2013; 12: 2226-2236.
8. **Venturelli S***, Berger A*, Böcker A, Busch C, Weiland T, Noor S, Leischner L, Schleicher S, Mayer M, Weiss TS, Bischoff SC, Lauer UM, Bitzer M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone proteins in human-derived hepatoblastoma cells. *PLoS One.* 2013;8: e73097.
9. Weiland T, Lampe J, Essmann F, **Venturelli S**, Berger A, Bossow S, Berchtold S, Schulze-Osthoff K, Lauer UM, Bitzer M. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses. *Int J Cancer.* 2014; 134: 235-243.
10. Schleich T, Rodemeister S, **Venturelli S**, Sinnberg T, Garbe C, Busch C. Decreased Plasma Ascorbate Levels in Stage IV Melanoma Patients. *Metab Nutr Oncol.* 2013; doi: 10.1055/s-0033-1348256.
11. Weiland T, Klein K, Zimmermann M, Speicher T, **Venturelli S**, Berger A, Bantel H, Königsrainer A, Schenk M, Weiss TS, Wendel A, Schwab M, Bitzer M, Lauer UM. Selective Protection of Human Liver Tissue in TNF-Targeting of Cancers of the Liver by Transient Depletion of Adenosine Triphosphate. *PLoS One.* 2012; 7: e52496.
12. Berger A*, **Venturelli S***, Kallnischkies M, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Weiss TS, Lauer UM, Bischoff SC, Bitzer M. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. *J Nutr Biochem.* 2013; 24: 977-985.
13. Schott S, Niessner H, Sinnberg T, **Venturelli S**, Berger A, Ikenberg K, Villanueva J, Meier F, Garbe C, Busch C. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells. *Int J Cancer.* 2012; 131: 2165-2174.
14. Weiland T, Berger A, Essmann F, Lauer UM, Bitzer M, **Venturelli S**. Kinetic tracking of therapy-induced senescence using the real-time cell analyzer single plate system. *Assay Drug Dev Technol.* 2012; 10: 289-295.
15. **Venturelli S**, Berger A, Weiland T, Zimmermann M, Häcker S, Peter C, Wesselborg S, Königsrainer A, Weiss TS, Gregor M, Fulda S, Lauer UM, Bitzer M. Dual antitumor effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. *Gut.* 2011; 60: 156-165.
16. Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, **Venturelli S**, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schitteck B, Garbe C, Kulms D, Meier F. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. *J Invest Dermatol.* 2011; 131: 468-479.
17. **Venturelli S***, Armeanu S*, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. *Cancer.* 2007; 109: 2132-2141.
18. Pathil A, Armeanu S, **Venturelli S**, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. *Hepatology.* 2006; 43: 425-434.
19. Armeanu S, Bitzer M, Lauer UM, **Venturelli S**, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific

induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. *Cancer Res.* 2005; 65: 6321-6329.

20. Armeanu S, Pathil A, **Venturelli S**, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. *J Hepatol.* 2005; 42: 210-217.

21. Geib T, Sauder C, **Venturelli S**, Hässler C, Staeheli P, Schwemmle M. Selective virus resistance conferred by expression of Borna disease virus nucleocapsid components. *J Virol.* 2003; 77: 4283-4290